HALO
Halozyme Therapeutics, Inc.
NASDAQ · USHealthcareBiotechnology
$77.09-0.93%
Price as of Jul 20, 2026
HALO profitability
Halozyme Therapeutics, Inc. profitability
Margins, returns on capital and operating-efficiency metrics from the latest trailing period.
Margins
- Gross margin
- 76.9%
- EBITDA margin
- 41.4%
- EBIT margin
- 57.0%
- Net margin
- 23.1%
- Free cash flow margin
- 44.3%
Returns
- Return on equity
- 158.8%
- Return on assets
- 13.1%
- Return on invested capital
- 36.3%
- Asset turnover
- 0.58x
Cash efficiency
- Cash from operations
- $677.4M
- Cash per share
- $2.69
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.